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Enteroaggregative Escherichia coli (EAEC) has been reported to cause traveler’s diarrhea and persistent diarrhea
in children in developing countries and in immunocompromised patients. To clarify the prevalence of EAEC
in traveler’s diarrhea, we studied 636 US, Canadian, or European travelers with diarrhea: 218 in Guadalajara,
Mexico (June–August 1997 and 1998), 125 in Ocho Rios, Jamaica (September 1997–May 1998), and 293 in
Goa, India (January 1997–April 1997 and October 1997–February 1998). Stool samples were tested for conven-
tional enteropathogens. EAEC strains were identified by use of the HEp-2 assay. EAEC was isolated in 26% of
cases of traveler’s diarrhea (ranging from 19% in Goa to 33% in Guadalajara) and was second only to entero-
toxigenic E. coli as the most common enteropathogen in all areas. Identification of EAEC reduced the number
of cases for which the pathogen was unknown from 327 (51%) to 237 (37%) and explained 28% of cases with
unknown etiology. EAEC was a major cause of traveler’s diarrhea in 3 geographically distinct study areas.
Diarrhea is the major travel-related disease in terms of
frequency and economic impact among people who
travel from industrialized countries to high-risk tropical
and subtropical developing regions of Latin America,
Africa, and Asia, with incidence rates as high as 40%–
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50% [1–3]. Various infectious agents have been iden-
tified as the primary cause of traveler’s diarrhea; bac-
terial enteropathogens cause ∼80% of cases of traveler’s
diarrhea with recognized etiology [1, 2]. Of these en-
teric bacteria, enterotoxigenic Escherichia coli (ETEC)
has been identified as the most common organism,
found in 20%–40% of travelers with diarrhea in dif-
ferent areas of the world [1, 2].
Enteroaggregative E. coli (EAEC) is a recently rec-
ognized pathogen within the group of E. coli that cause
diarrhea [4]. Mathewson et al. [5] first recognized
EAEC as a cause of traveler’s diarrhea in 1985. To assess
the worldwide prevalence, we used the HEp-2 cell assay
[6, 7] to identify EAEC in stool samples from travelers
with diarrhea in 3 different regions of the world.
POPULATION, MATERIALS, AND
METHODS
Population. The study population included adults
from the United States, Canada, of Europe with dia-
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Table 1. Prevalence of enteropathogens in cases of traveler’s
diarrhea at 3 locations.
Infecting
pathogen(s)
No. of patients (prevalence, %), by location
Guadalajara,
Mexico
Ocho Rios,
Jamaica
Goa,
India Total
ETEC 83 (38) 37 (30) 73 (25) 193 (30)
EAEC 73 (33) 33 (26) 56 (19) 162 (26)
Othersa 10 (5) 4 (3) 30 (10) 44 (7)
Mixedb 40 (18) 7 (6) 79 (27) 126 (20)
None identifiedc 76 (35) 53 (42) 108 (37) 237 (37)
Totald 218 (100) 125 (100) 293 (100) 636 (100)
NOTE. EAEC, enteroaggregative Escherichia coli; ETEC, enterotoxigenic
E. coli.
a Includes Salmonella species, Shigella species, Campylobacter jejuni, Vibrio
species, Aeromonas hydrophila, Plesiomonas shigelloides, Entamoeba histo-
lytica, Cryptosporidium parvum, Giardia lamblia, and rotavirus.
b Mixed infections comprised patients with 11 enteric pathogen.
c No pathogen indicates cases of traveler’s diarrhea with a nonidentified
etiologic agent.
d Some of the patients had mixed infections.
rrhea who visited one of our traveler’s health clinics in Gua-
dalajara, Mexico; Ocho Rios, Jamaica; or Goa, India. In Gua-
dalajara, 94 students from the United States were enrolled in
June–August 1997, and 124 more were recruited in
June–August 1998. A total of 125 international tourists were
enrolled in Jamaica in September 1997–May 1998. In Goa, 293
travelers with diarrhea were evaluated during 2 different periods
of time: January–April 1997 and October 1997–February 1998.
Subjects in Mexico and Jamaica participated in double-blind,
randomized clinical trials that tested antidiarrheal compounds
[8, 9]. Patients in Goa were recruited as part of a collaborative
study of diarrhea conducted by the Center for Infectious Dis-
eases at the University of Texas–Houston Medical School and
School of Public Health and the Institute of Social and Pre-
ventive Medicine at the University of Zurich, Zurich, Switzer-
land [10].
In the studies, acute traveler’s diarrhea was defined as the
passage of 3 unformed stools in 24 h within 72 h of onset
of symptoms, together with 1 additional clinical manifesta-
tion of enteric disease, such as nausea, vomiting, abdominal
cramps or pain, tenesmus, stool urgency, or dysentery. Eligible
subjects included men or women 18 years old. Subjects were
not enrolled if they had taken an antimicrobial agent with
expected activity against bacterial enteropathogens within the
previous week.
Stool examination. After a qualified patient signed a writ-
ten consent form, a stool specimen was collected. These sam-
ples were submitted to the field-site laboratory, where they
were examined by published methods [5] for conventional
bacterial enteric pathogens, including Shigella species, Sal-
monella species, Vibrio species, Campylobacter jejuni, Yersinia
enterocolitica, Aeromonas species, and Plesiomonas shigelloides.
Entamoeba histolytica, Cryptosporidium species, and Giardia
lamblia were identified by means of EIA. The presence of
rotavirus and other viral enteric pathogens were not sought in
this study. Five E. coli–like colonies were retrieved from
MacConkey agar plates from each stool sample and were in-
oculated into individual peptone stabs. They were transported
to the Center for Infectious Diseases, University of Texas–
Houston, for further identification. Oligonucleotide probes for
heat-labile and heat-stable enterotoxins of ETEC were hybrid-
ized with the 5 E. coli–like colonies for the detection of ETEC
[11].
HEp-2 adherence assay. At least 3 of the 5 E. coli–like
colonies per stool sample were tested for the presence of EAEC
by looking for a characteristic pattern of adherence to cultured
HEp-2 cells [4, 6, 7, 12]. We used the method of Cravioto et
al. [6], which was demonstrated to be the optimal procedure,
according to a comparative study by Vial et al. [12]. In brief,
a chamber slide (Dynatek) was seeded with HEp-2 cells (ATCC)
that had been grown at 37C in 5% CO2 on minimum essential
medium (Gibco BRL) supplemented with 10% fetal calf serum.
E. coli to be tested were grown overnight at 37C in tryptic soy
broth (BBL Microbiology) with 1% d-mannose. The cell culture
medium in the chamber slide then was replaced with minimum
essential medium containing 1% d-mannose without antibi-
otics; E. coli was added and was incubated at 37C for 3 h. The
slide was washed vigorously 3 times with PBS, was fixed with
100% methanol, and was stained with Wright-Giemsa. Positive
and negative controls were included in each assay. Finally, each
E. coli strain was twice examined in a blinded fashion. A sample
was interpreted as positive for EAEC if it showed the charac-
teristic “stacked-brick” aggregative appearance, as described by
Nataro et al. [7].
Pulsed-field gel electrophoresis (PFGE). Thirty EAEC
strains from Guadalajara, Mexico (obtained in the summer of
1998), were tested by means of PFGE [13], to look for inter-
strain variability.
RESULTS
Table 1 shows the prevalence of the various enteric pathogens
in the 3 study areas. EAEC was identified in 162 (26%) of 636
cases of traveler’s diarrhea—19% in Goa, 26% in Jamaica, and
33% in Guadalajara. Seventy-three of the 162 EAEC cases
(45%) were isolated in Guadalajara: 19 patients in 1997 and
54 during the summer of 1998. EAEC accounted for 26% of
cases of traveler’s diarrhea when the 3 areas were combined,
and only ETEC was more prevalent, found in 30% of the cases.
ETEC was responsible for 48% (193 of 399) of the pathogen-
identifiable illness, whereas EAEC was found in 41% of the
cases with an established etiology. Overall, the number of cases
caused by all the other bacterial enteric pathogens combined
1708 • CID 2001:32 (15 June) • Adachi et al.
Table 2. Prevalence of infection with enteroaggregative Esche-
richia coli and coinfection with other enteric pathogens in pa-
tients with diarrhea at 3 locations.
Infecting
pathogen(s)
No. of patients (prevalence, %), by location
Guadalajara,
Mexico
Ocho Rios,
Jamaica
Goa,
India Total
EAEC alone 43 (59) 26 (79) 21 (38) 90 (56)
EAEC and ETEC 26 (36) 1 (3) 14 (25) 41 (25)
EAEC and othersa 4 (5) 6 (18) 21 (38) 31 (19)
Total EAEC 73 (100) 33 (100) 56 (100) 162 (100)
NOTE. EAEC, enteroaggregative E. coli; ETEC, enterotoxigenic E. coli.
a Mixed infection with EAEC and non-ETEC enteric pathogens.
was less than the number of cases caused by ETEC or EAEC,
which were isolated from 148 (23%) of all the subjects with
traveler’s diarrhea. In general, most of the defined non-ETEC,
non-EAEC pathogens identified in our study were obtained
from stool samples from tourists with traveler’s diarrhea visiting
Goa.
In the 3 regions studied, EAEC was the only pathogen iso-
lated from 90 (14%) of 636 patients and was found to be mixed
with other enteric pathogens in 72 (11%) patients. Coinfection
of EAEC and ETEC accounted for 41 of these 72 mixed in-
fections (table 2). Infection by EAEC alone occurred more often
in Jamaica (79%) and Guadalajara (59%) than in Goa (38%).
Coinfection by EAEC and ETEC occurred most commonly in
Guadalajara, whereas mixed infection with other enteropatho-
gens was more common in Goa and Jamaica.
The identification of EAEC as an enteric pathogen explained
the etiology of 28% of cases of diarrhea in patients who
otherwise had an unidentified pathogen. By looking for EAEC
in all diarrhea samples using the HEp-2 call adherence assay,
we were able to reduce the number of patients with an unknown
etiologic agent from 51% of 636 patients to 37%. This reduc-
tion was similar in Guadalajara (55%–35%) and in Jamaica
(63%–42%). Because of the lower number of patients with
EAEC as the only pathogen identified, this reduction was less
evident in Goa (44%–37%).
Finally, we tested 30 of 32 strains of EAEC that were isolated
as the only pathogen from subjects with traveler’s diarrhea in
Guadalajara during the summer of 1998 for strain differences.
By use of PFGE, our results showed a highly heterogeneous
DNA pattern among the EAEC strains, with no more than 2
similar bands between the different isolates.
DISCUSSION
EAEC was identified in the present study as an important cause
of traveler’s diarrhea in Mexico, Jamaica, and India. EAEC was
the second most common enteropathogen isolated at all 3
locations.
Because coinfection with EAEC and other recognized enteric
pathogens was common (72 of 162 patients), it is not possible
to define EAEC as the true pathogen in these patients. However,
in 90 of 162 patients, EAEC was the sole pathogen, and iden-
tifying this pathogen explained the etiology of ∼30% of the
cases for which the pathogen was unknown. Identification of
EAEC as a pathogen that causes diarrhea helps to explain a
previous observation by our group, that diarrhea in patients
for which no pathogen is identified improves with antimicrobial
therapy [14, 15].
In 1985, Mathewson et al. [5] first described EAEC to be
responsible for 14.9% of diarrhea in a US student population
visiting Guadalajara. The results of the present study, taken
with this finding, confirm that EAEC is a consistently important
pathogen causing traveler’s diarrhea in Guadalajara, Mexico.
Although EAEC was the second most common pathogen
identified in Goa, it was least commonly the sole enteric patho-
gen and was most commonly isolated with other enteropatho-
gens, compared with the pattern of infection in Guadalajara
and Jamaica. It appears that exposure to multiple enteropatho-
gens is more common in Goa than in the other locations.
Although different candidate virulence factors have been re-
ported in EAEC strains, such as the production of EAEC heat-
stable toxin, plasmid-encoded enterotoxin or a novel cryo-
hemagglutinin, or the presence of a novel flagellin or an ag-
gregative adherence fimbria I or II, most EAEC strains have
none of these factors [16–20]. These data and the finding of
no homogeneous DNA pattern in the EAEC strains from Gua-
dalajara support the probability that EAEC strains are a group
of heterogeneous E. coli that share few characteristics, with the
exception of the distinctive aggregative adherence to HEp-2
cells. Further studies of the molecular biology of these bacteria
should provide additional knowledge about its epidemiology,
diagnosis, prevention, and treatment.
Although some studies have questioned the pathogenic role
of these strains because of the similar frequency of isolating
EAEC from patients with diarrhea and from asymptomatic con-
trol subjects [21, 22], the findings of more recent studies sup-
port the hypothesis that it has a true pathogenic role. This role
has been confirmed in outbreaks and in volunteer studies [5,
23], but the strains have heterogeneous virulence [23].
EAEC has been implicated as an etiologic agent in persistent
diarrhea in children in developing countries [24, 25] and in
patients with AIDS-associated chronic diarrhea in the United
States [26] and in Africa [27]. On the basis of the present study
and others [28, 29], the organism appears to be an important
cause of traveler’s diarrhea. It is uncertain how important EAEC
is as a cause of sporadic and epidemic diarrhea in industrialized
areas [30]. Further evidence of the organism’s pathogenicity is
the finding that therapy with fluoroquinolones shortened the
length of bouts of diarrhea in patients with AIDS [26] and in
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international travelers with EAEC diarrhea [28]. Our study
indicates the importance of EAEC as a cause of traveler’s di-
arrhea in these diverse regions of the world.
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